Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 706 to 720 of 2006 results for nice guidelines

  1. Cenobamate for treating focal onset seizures in epilepsy (TA753)

    Evidence-based recommendations on cenobamate (Ontozry) for treating focal onset seizures with or without secondary generalised seizures in adults with drug-resistant epilepsy that has not been adequately controlled with at least 2 antiseizure medicines.

    Technology appraisal guidance
    Last updated
    24 July 2025
    View recommendations

    Sections for TA753

  2. Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA341)

    Evidence-based recommendations on apixaban (Eliquis) for treating and preventing recurrent deep vein thrombosis or pulmonary embolism in adults.

    Technology appraisal guidance
    Published
    4 June 2015
    View recommendations

    Sections for TA341

  3. Who can register as a stakeholder?

    Find out more about the types of organisations that can register to be a stakeholder at NICE.

  4. Who can register as a stakeholder?

    Find out more about the types of organisations that can register to be a stakeholder at NICE.

  5. Capsule sponge tests for detection of Barrett's oesophagus and oesophageal cancer (provisional title)

    In development Reference number: GID-HTE10070 Expected publication date: TBC

    Health technology evaluations
    In development

  6. Modular updates

    Our modular updates framework ensures flexibility and consistency in updating our manuals and helps prioritise important updates.

  7. Using NICE guidance in social work: scenarios

    Home Implementing NICE guidance Social care...

  8. Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis (TA386)

    Evidence-based recommendations on ruxolitinib (Jakavi). This drug is for adults with disease-related splenomegaly or symptoms caused by primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis, only if they have intermediate-2 or high-risk disease.

    Technology appraisal guidance
    Published
    23 March 2016
    View recommendations

    Sections for TA386

  9. VibraTip for testing vibration perception to detect diabetic peripheral neuropathy (HTG362)

    Evidence-based recommendations on VibraTip for testing vibration perception to detect diabetic peripheral neuropathy.

    HealthTech guidance
    Last updated
    1 March 2015
    View recommendations

    Sections for HTG362

  10. Subscribe to our GP reference panel

    Subscribe to our GP reference panel and contribute to the development of NICE guidance in a quick and easy way.

  11. Quality improvement resource for adult social care

    Home Implementing NICE guidance Social care...

  12. Speaking engagements

    Ask an expert from NICE International, part of the UK's National Institute for Health and Care Excellence, to speak at a healthcare event in your country

  13. Prioritisation board decisions 2025

    Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.

  14. Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA393)

    Evidence-based recommendations on alirocumab (Praluent) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.

    Technology appraisal guidance
    Published
    22 June 2016
    View recommendations

    Sections for TA393

  15. Freelite assays for diagnosing multiple myeloma and related conditions (terminated assessment) (HTG619)

    NICE no longer plans to develop guidance on Freelite assays for diagnosing multiple myeloma and related conditions in primary care.

    HealthTech guidance
    Published
    30 March 2022

    Sections for HTG619